# OrthoPulse

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/orthopulse

- Industry: Healthcare Specialists
- Headquarters: Austria
- Website: www.orthopulse.com
- Total disclosed funding: $19M
- Latest round: Seed (Nov 13, 2024)
- Investors on record: 4

## About

Biolux Research Ltd. is an Austria-based medical technology firm focused on innovative orthodontic solutions, notably the OrthoPulse®, which accelerates orthodontic treatment using near infrared light technology.Founded in 2003 and headquartered in Austria, Biolux Research Ltd. specializes in light-accelerated orthodontics. The company has secured funding through three deals, with the most recent being a Seed round on November 13, 2024, totaling USD 4.5 mn from investors Redalpine and Revere Partners.Biolux Research's flagship product, the OrthoPulse®, is a medical device that employs near infrared light technology to expedite orthodontic treatment for braces and clear aligners. This device uses photobiomodulation to stimulate bone around the roots of teeth, facilitating tooth movement and alleviating pain. It requires only 10 minutes of daily use, appealing to orthodontists, dental practices, and patients across the United States and Europe, where it has received both FDA clearance and EU MDR approval.Biolux Research generates revenue through the sale of the OrthoPulse® to orthodontic practices and directly to consumers, primarily utilizing a B2B model. Orthodontists purchase the device for their practices to enhance treatment offerings, while a mobile application may provide additional support for tracking treatment progress. The pricing structure includes the device and associated services, fostering a direct relationship with clients to improve treatment outcomes and patient satisfaction.Following a Seed funding round in November 2024 that raised USD 4.5 mn, Biolux Research Ltd. plans to utilize the funds to develop a smart digital platform for OrthoPulse®, advance clinical research, and enhance its light-accelerated orthodontic technology. The focus will be on improving treatment outcomes and expanding into the U.S. market.

## Funding rounds

- Seed, Nov 13, 2024, $4.5M — Redalpine, Revere Partners
- Series A, Apr 30, 2019, $14M — Venrock, Correlation Ventures

## Investors

- Venrock (https://capitalatlas.ai/funds/venrock) — Series A
- Correlation Ventures (https://capitalatlas.ai/funds/correlation-ventures) — Series A
- Redalpine (https://capitalatlas.ai/funds/redalpine) — Seed
- Revere Partners (https://capitalatlas.ai/funds/revere-partners) — Seed